Besides, the addition of everolimus to exemestane can overcome resistance due to constitutive activation of the PI3K/AKT/mTOR pathway after prior therapy with letrozole or anastrozole in HR‐positive, HER2‐negative breast cancer.630. Here, AKT1 is linked to breast carcinoma.